Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948976 | 0.87 | HTR2A (0.50) | GPR119HTR2AHTR6HTR2BPIK3CA | |
| SCHEMBL951512 | 0.83 | HTR2A (0.48) | GPR119HTR2AHTR6HTR2BPIK3CA | |
| SCHEMBL952720 | 0.81 | HTR6 (0.55) | HTR2AHTR6HTR2BPIK3CAHTR1A | |
| SCHEMBL949355 | 0.81 | HTR6 (0.45) | GPR119HTR2AHTR6HTR2BPIK3CA | |
| SCHEMBL2195197 | 0.78 | HTR2A (0.59) | GPR119HTR2AHTR6PIK3CAHTR1A | |
| SCHEMBL949399 | 0.77 | HTR6 (0.60) | HTR2AHTR6HTR2BHTR1ADRD2 | |
| SCHEMBL3745125 | 0.77 | HTR2A (0.49) | GPR119HTR2AHTR6PIK3CANR1H2 | |
| SCHEMBL2197307 | 0.77 | HTR2A (0.63) | GPR119HTR2AHTR6PIK3CAHTR1A | |
| SCHEMBL3827483 | 0.75 | PIK3CA (0.66) | GPR119HTR6PIK3CATGFBR1MAPT | |
| SCHEMBL17580926 | 0.75 | HTR2A (0.47) | GPR119HTR2AHTR6PIK3CANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242102-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-08-14 | — | — | US | disclosed |
| EP-2139880-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2139880-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116831-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR2C, HTR3B, HTR1B | GPR119 530/4885HTR2A 5/4885HTR6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.